A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 27, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

Head and Neck Squamous Cell CarcinomasSolid Tumor

Interventions

DRUG

BL-B16D1

Administration by intravenous infusion for a cycle of 3 weeks.

Trial Locations (1)

RECRUITING

Shanghai East Hospital, Shanghai

All Listed Sponsors

collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY